CRMD vs. CPRX, GMTX, HCM, RXRX, TWST, AMRX, KYMR, EWTX, NAMS, and JANX
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), HUTCHMED (HCM), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Edgewise Therapeutics (EWTX), NewAmsterdam Pharma (NAMS), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs.
CorMedix (NASDAQ:CRMD) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
CorMedix presently has a consensus target price of $15.67, suggesting a potential upside of 28.73%. Catalyst Pharmaceuticals has a consensus target price of $32.86, suggesting a potential upside of 44.24%. Given Catalyst Pharmaceuticals' higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than CorMedix.
In the previous week, CorMedix had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for CorMedix and 5 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.76 beat CorMedix's score of 0.49 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 5.2% of CorMedix shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Catalyst Pharmaceuticals has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CorMedix has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
Catalyst Pharmaceuticals received 474 more outperform votes than CorMedix when rated by MarketBeat users. However, 75.00% of users gave CorMedix an outperform vote while only 74.89% of users gave Catalyst Pharmaceuticals an outperform vote.
Catalyst Pharmaceuticals has a net margin of 31.01% compared to CorMedix's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat CorMedix's return on equity.
Summary
Catalyst Pharmaceuticals beats CorMedix on 13 of the 17 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CRMD Stock Alerts